New eye injection trial targets rare lymphoma
Disease control
Recruiting now
This study is testing an experimental injection (ADX-2191) directly into the eye to treat primary vitreoretinal lymphoma, a rare cancer. It will compare two different dosing schedules to see which is safer and more effective at clearing cancer cells. The trial is recruiting about…
Phase: PHASE3 • Sponsor: Aldeyra Therapeutics, Inc. • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC